# Amgen

生物技术先驱，1980年创立——安进、普罗利亚和PCSK9抑制剂瑞百安；全球最大商业单抗生产能力之一；GMP单抗生物制造的历史标杆；NASDAQ: AMGN。

Source: https://cn.bioecon.ru/companies/amgen/
Updated: 2026-06-19

- 国家: United States
- 营收: $33.4B
- 员工: ~24,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 总部 | 美国加利福尼亚州Thousand Oaks | https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf |
| 员工人数 | 全球约31,500人 | https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf |
| 营收 | $36.8 billion（2025年） | https://www.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.ashx, https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf |
| 生产基地 | 美国（含波多黎各、罗德岛、俄亥俄州、加利福尼亚州）、爱尔兰、荷兰和新加坡 | https://investors.amgen.com/static-files/43d5c346-88b9-44b3-9201-79514b22087a |
| 产能 | 利用最先进的设施扩大并优化网络；波多黎各洪科斯是全球最大的设施之一；近期新增俄亥俄州和北卡罗来纳州设施 | https://investors.amgen.com/news-releases/news-release-details/amgen-announces-fda-licensure-two-new-manufacturing-facilities, https://www.amgen.com/newsroom/press-releases/2026/05/amgen-announces-additional-300-million-us-manufacturing-investment-totaling-nearly-2-billion-over-the-last-year |
| 监管批准 | 包括Enbrel、Prolia和Repatha在内的产品已获得FDA及国际监管机构批准 | https://investors.amgen.com/static-files/43d5c346-88b9-44b3-9201-79514b22087a, https://www.amgen.com/about/amgen-history, https://www.fiercepharma.com/pharma/amgen-s-repatha%C2%AE-evolocumab-approved-as-first-pcsk9-inhibitor-japan-for-treatment-of-high |

独立来源: fiercepharma.com

## 技术

- [生物药 (Biologics)](https://cn.bioecon.ru/technology/biologics/)